^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Topoisomerase II-beta inhibitor

    Related drugs:
    2ms
    Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=22, Completed, Moleculin Biotech, Inc. | Active, not recruiting --> Completed | N=63 --> 22
    Trial completion • Enrollment change
    |
    naxtarubicin (L-ANN)
    8ms
    L-Annamycin for Injection in Combination with Cytarabine Injection As Second Line Therapy for Remission Induction in Adult Subjects with Refractory/relapsed AML (clinicaltrials.gov)
    P2/3, N=334, Recruiting, Moleculin Biotech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    naxtarubicin (L-ANN)
    11ms
    L-Annamycin for Injection in Combination with Cytarabine Injection As Second Line Therapy for Remission Induction in Adult Subjects with Refractory/relapsed AML (clinicaltrials.gov)
    P2/3, N=334, Not yet recruiting, Moleculin Biotech, Inc.
    New P2/3 trial
    |
    naxtarubicin (L-ANN)
    1year
    Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, Moleculin Biotech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    naxtarubicin (L-ANN)
    1year
    Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases (clinicaltrials.gov)
    P1/2, N=36, Completed, Moleculin Biotech, Inc. | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: May 2024 --> Aug 2024
    Trial completion • Phase classification • Trial completion date
    |
    naxtarubicin (L-ANN)